Galanin’s implications for post-stroke improvement

Juhyun Song¹,², Oh Yoen Kim²,³
¹Department of Biomedical Sciences, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju, ²Human Life Research Center, Dong-A University, Busan, ³Department of Food Science and Nutrition, Dong-A University, Brain Busan 21, Busan, Korea

Abstract: Stroke leads to a variety of pathophysiological conditions such as ischemic infarct, cerebral inflammation, neuronal damage, cognitive decline, and depression. Many endeavors have been tried to find the therapeutic solutions to attenuate severe neuropathogenesis after stroke. Several studies have reported that a decrease in the neuropeptide regulator ‘galanin’ is associated with neuronal loss, learning and memory dysfunctions, and depression following a stroke. The present review summarized recent evidences on the function and the therapeutic potential of galanin in post-ischemic stroke to provide a further understanding of galanin’s role. Hence, we suggest that galanin needs to be considered as a therapeutic factor in the alleviation of post-stroke pathologies.

Key words: Galanin, Post-stroke, Depression, Inflammation, Cognitive decline

Received September 21, 2016; Revised October 16, 2016; Accepted December 8, 2016

Introduction

Stroke represents one of five common causes of death in the world although its incidence and mortality have been decreased last a few decades [1-3]. Stroke causes cerebral dysfunction that leads to irreversible brain injury [4]. Furthermore, post-ischemic inflammation which is an essential response in the pathophysiology of stroke [5], may lead to the clearance of debris caused by necrotic cell death [6] and also aggravate sequential neuropathology after stroke [7, 8]. Post-stroke depression is also a significant long-term issue in stroke patients [9, 10]. According to recent studies, the prevalence of post-stroke depression ranges from 25% to 79% among stroke patients, and depressive symptoms are present in approximately 33% of stroke patients [2, 11]. The cognitive impairment in stroke patients is related to the progression of post-stroke neuro-pathophysiology [12, 13], and the frequency of cognitive impairment is more than four times higher in stroke patients than that in patients who have not suffered from a stroke [14]. The prevalence of post-stroke dementia in the first year after stroke is approximately 7% among the first-time stroke patients [15].

Many therapeutic strategies including glutamate receptor antagonists and calcium channel blockers have been tested to alleviate and prevent brain damage following stroke [16]. The neuropeptide, galanin [17] exerts its effects by binding to galanin receptors throughout the central and peripheral nervous system [18, 19]. Galanin has been reported as a regulator of feeding [20] and a protector of neuronal cells against oxidative stress [21]. Galanin controls the secretion of several stress hormones [22] and may contribute to cognitive dysfunction [23]. Stroke leads to severe pathogenic disorders such as depression [9, 24] and memory dysfunction [25]. In an ischemic stroke model, one study found that middle cerebral artery occlusion (MCAO) injury leads to a decrease in galanin immunoreactivity in the ischemic brain 3 days after a transient MCAO. Moreover, several studies suggest that galanin may...
have a potential to improve the learning and memory decline [26, 27]. In this review, we summarize the recent evidences on galanin’s various roles in the brain after stroke. These findings highlight the importance for further research on the role of galanin in post-stroke improvement.

**Galanin**

Galanin is a neuropeptide composed of 30 amino acids in humans [17, 28]. It is widely distributed throughout the central and peripheral nervous system [18], and localized to brain regions implicated in behavioral function including the locus coeruleus, forebrain, amygdala, and hypothalamus [17, 29]. Galanin is encoded by galanin-like peptide (GALP) [30] and exerts its biological action by binding with three G protein-coupled galanin-receptor subtypes (GalR1, GalR2, and GalR3) [31, 32]. These receptor subtypes are expressed in the midbrain and limbic regions, where they mediate stress-related behaviors [20, 33-35]. Cheung et al. [20] shows that injection with galanin may control the feeding in animals. Galanin is negatively regulated by leptin which attenuates food intake and controls body weight [20]. In addition, galanin has a neuroprotective effect on hippocampal neurons by reducing cell death [36] through GalR2 [36], and regulates inflammatory mechanism [37]. Galanin is secreted when neurons were stimulated by behavioral and pharmacological provocation [23]. Moreover, galanin regulates the secretion of glucocorticoids and catecholamines in response to stress in rodents and humans [22, 38], and suppresses the secretion of norepinephrine, serotonin, and dopamine neurons in forebrain regions [39, 40]. Several studies have focused on the relationship between galanin and neurophysiological/neuroendocrine functions [41, 42]. Here in this review, we focused on the relationship between galanin and a variety of neurophysiological/neuroendocrine functions in post-stroke brain conditions.

**Galanin and Stroke**

MCAO injury is a common method used in the *in vivo* ischemic stroke animal model. Another study using the MCAO model showed that intracerebroventricular administration of a GalR2 or GalR3 agonist leads to a reduction in the ischemic infarct size [43]. Numerous studies using stroke models show the decreases of galanin and GalR gene expression in the brain after ischemic stroke [43, 44]. For example, one study reported that GalR1 mRNA levels were significantly decreased 24 hours after MCAO injury [45]. In another MCAO stroke model without reperfusion, only low levels of galanin were observed 24 hours after injury in infarct regions such as the caudate nucleus [46]. Furthermore, Holm et al. [43] demonstrated that galanin system can be activated in an ischemic brain lesion via a continuous infusion of a galanin agonist for 3 or 7 days. Based on these findings, future studies for the investigation of the galanin system in the post-stroke brain are needed.

**Galanin in Post-stroke Depression**

Post-stroke depression leads to functional disability [24], poorer rehabilitation outcomes [47], and increased morbidity and mortality [9, 48]. Several studies have revealed that ischemic stroke is one of the leading causes of depression [49, 50]. In a retrospective study, patients with stroke showed rates of recurrence throughout the time course, and 55% of them had an incidence of post-stroke depression over 15 years [51]. Depression symptoms may deteriorate during the chronic phase after stroke [52, 53]. Galanin is considered to be a depression-related peptide [54], and plasma galanin is considered as a biomarker for diagnosing major depressive disorder [33]. Galanin receptors which act via cAMP formation [55] and the cyclic AMP responsive element binding (CREB) signaling pathway [56, 57] modulate brain-derived neurotrophic factor production which is associated with depression [58]. Several studies including animal behavioral [59, 60] and human clinical studies [61] have indicated that galanin plays crucial roles in stress, depression, and anxiety. A change in galanin expression in rat hippocampus alters mild depression, and subsequently leads to changes in depression-related behaviors [54, 62]. Moreover, galanin genes are involved in depression-related phenotypes [63]. Current studies suggest that polymorphisms in the upstream region of the *GAL* gene may affect the expression of galanin in brain regions implicated in depression including the amygdala and hypothalamus [29, 64]. Given this evidence for a relationship between galanin and depression, galanin may be associated with post-stroke depression.

**Galanin in Post-stroke Inflammation**

Inflammation following ischemic stroke exaggerates vascular dysfunction and leads to neuronal cell death [65]. Post-ischemic inflammation is a common process after ischemic...
stroke and significantly associated with post-stroke prognosis [5, 66]. Ischemic stroke triggers cellular damage in the brain via inflammation occurring over hours to days [67]. Many studies have found that stroke is followed by an inflammatory response that includes the secretion of inflammatory cytokines and leukocytes, monocyte infiltration in the brain, and activation of glia cells [68-71]. Leukocyte infiltration in the brain boosts inflammatory activation of various cells such as microglia and astrocytes [72]. Recent studies have explored the ability of neuropeptides with physiological functions such as galanin peptides, to prevent and alleviate post-stroke inflammatory responses [73, 74]. Several studies have demonstrated that upregulation of GalR1 is related to the increased expression of nuclear factor (NF)-κB, which is an inflammatory signaling molecule in inflammatory animal models [75, 76]. The activation of the mitogen-activated protein kinases/extracellular signal-regulated kinase/extracellular signal-regulated protein kinase 1/2 pathway via GalR1 affects the induction of the cell cycle and suppression of cyclin D1 [77]. In vivo studies have also suggested that GalR1 is associated with the modulation of CREB [56] and c-fos [78] in the brain. In addition, the regulatory function of GalR2-mediated galanin signaling has been reported in inflammatory, neuropathic, and acute pain models [79]. GalR2-related apoptosis is triggered by the induction of the pro-apoptotic Bcl-2 protein Bim [80]. Several studies have suggested that treatment with galanin may decrease the expression of pro-inflammatory cytokines [81] such as tumor necrosis factor-α and interleukin-1β, and increase anti-inflammatory responses via GalR2 [82]. Consequently, galanin may act as a regulator of inflammation following ischemic stroke by controlling the secretion of inflammatory cytokines.

**Galanin in Post-stroke Cognitive Dysfunction**

Post-stroke dementia is defined as any dementia that occurs following a stroke [14]. Some studies have reported that up to 70% of stroke patients suffer from cognitive impairments [83, 84]. One clinical study indicated that the pathogenesis of Alzheimer’s disease was observed in over one-third of patients with dementia after stroke [85, 86]. Post-stroke depression is a complex psychiatric disorder which causes the delay in functional recovery from rehabilitation and increased cognitive impairment [26, 87]. Galanin and galanin receptors are located in brain areas directly related to cognitive function [88, 89]. The effects of galanin on memory in the brain have been studied [18, 90]. Galanin improves learning and memory via the modulation of the density of muscarinic receptors in hippocampal areas [91]. One in vitro study demonstrated that galanin increases the protein expression of M1 muscarin-

---

**Fig. 1.** The schematic image about galanin effect on post-stroke. After stroke, galanin binds galanin receptors such as GalR1, GalR2, and GalR3 and affects several signaling pathways. Galanin regulates CREB signaling and modulates BDNF secretion in neuron, and subsequently contributes to the improvement of post-stroke depression. In addition, galanin induces NF-κB and ERK/MAPK signaling and controls the production of pro- and anti-inflammatory cytokines and subsequently reduces post-stroke inflammation. Finally, galanin ameliorates post-stroke cognitive declines by regulating acetylcholine secretion and inhibiting neuronal cell loss. BDNF, brain-derived neurotrophic factor; CREB, cyclic AMP responsive element binding; NF-κB, nuclear factor-κB; ERK/MAPK, mitogen-activated protein kinases/extracellular signal-regulated kinase; GalR, galanin receptor.
ic acetylcholine receptors in primary cortical neurons [92]. In vivo studies show that galanin administered to rat hippocampus improves learning and memory on the Morris water maze test [93] and the administration of galanin improves cognitive function in mice by altering the step-down latency of passive avoidance [94]. In addition, galanin suppresses K+-stimulated acetylcholine release in the ventral hippocampus and cortical regions [95, 96], but increases the secretion of acetylcholine in the hippocampus when it is infused in Broca’s area in rats [90]. Galanin knock-out mice also exhibit a decrease in the secretion of acetylcholine in the hippocampus, and cognitive decline on behavioral tests such as the Morris water maze test [97] and the object-in-place memory task [98]. Furthermore, galanin inhibits neuronal cell loss in regions of the brain related to cognition such as cerebral cortex, basal forebrain, amygdala [99]. In addition, improved cognitive function was associated with higher levels of galanin in the cerebrospinal fluid [100]. Taken together, these findings suggest that galanin could improve cognitive impairment following ischemic stroke.

Conclusions

Inflammation, cognitive impairment, and depression following stroke are crucial issues in the study of post-stroke pathogenesis. To improve the various pathophysiological conditions following a stroke, several studies have investigated fine regulators from neurotransmitters, neuropeptides, hormones, and factors in ion channel pathways that attenuate post-stroke pathogenesis. Galanin is an orexigenic peptide that may control food intake and stress-mediated behaviors such as depression. Here, we focused on the various functions of galanin in post-stroke-related pathophysiologies. Consequently, this review suggests three notable post-stroke roles of galanin: (1) galanin improves depression by promoting the secretion of neurotrophic factors and restricting neuronal cell death under post-stroke oxidative stress; (2) galanin ameliorates the post-stroke inflammation response by attenuating the production of pro-inflammatory cytokines and regulating CREB, c-fos, and NF-kB signaling; and (3) galanin improves cognitive decline by stimulating the activity of cholinergic neurons and attenuating neuronal cell damage (Fig. 1). Although the function of galanin in post-stroke condition is not fully understood, further studies on the function of galanin after an ischemic stroke may reveal the potential for galanin as a therapeutic factor to improve post-stroke pathology.

Acknowledgements

This study was supported by the National Research Foundation of Korea Grant funded by the Korean Government (2016R1A2B4013627).

References

1. Barnes C, Newall F, Furmedge J, Mackay M, Monagle P. Arterial ischaemic stroke in children. J Paediatr Child Health 2004;40:384-7.
2. Bourgeois JA, Hilty DM, Chang CH, Wineinger MA, Servis ME. Poststroke neuropsychiatric illness: an integrated approach to diagnosis and management. Curr Treat Options Neurol 2004;6:403-20.
3. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O’Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinhohara Y, Witt E, Ezzati M, Naghavi M, Murray C. Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Expert Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2014;383:245-54.
4. Zheng Z, Lee JE, Yenari MA. Stroke: molecular mechanisms and potential targets for treatment. Curr Mol Med 2003;3:361-72.
5. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010;67:181-98.
6. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011;17:796-808.
7. Bohacek I, Cordeau P, Lalancette-Hébert M, Gorup D, Weng YC, Gajovic S, Kriz J. Toll-like receptor 2 deficiency leads to delayed exacerbation of ischemic injury. J Neuroinflammation 2012;9:191.
8. Shanta SR, Choi CS, Lee JH, Shin CY, Kim YJ, Kim KH, Kim KP. Global changes in phospholipids identified by MALDI MS in rats with focal cerebral ischemia. J Lipid Res 2012;53:1823-31.
9. Ayerbe L, Ayis S, Rudd AG, Heuschmann PU, Wolfe CD. Natural history, predictors, and associations of depression 5 years after stroke: the South London Stroke Register. Stroke 2011;42:1907-11.
10. Wei JJ, Xu W, Peng Y, Shi G, Basturk O, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, Pellicer A, Rhim JS, Melamed J, Lee P. Regulation of HMGAI expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 2011;17:1297-305.
11. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-40.
12. Farr TD, Wegener S. Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical
12. Kofler B, Liu ML, Jacoby AS, Shine J, Iismaa TP. Molecular
discovery of galanin. J Cereb Blood Flow Metab 2010;30:703-17.
13. Gottesman RF, Hillis AE. Predictors and assessment of cogni-
tive dysfunction resulting from ischaemic stroke. Lancet Neurol
2010;9:895-905.
14. Erkinjuntti T. Vascular cognitive deterioration and stroke. Cere-
brovasc Dis 2007;24 Suppl 1:189-94.
15. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors
associated with pre-stroke and post-stroke dementia: a system-
atic review and meta-analysis. Lancet Neurol 2009;8:1006-18.
16. Jeyaseelan K, Lim KY, Armugam A. Neuroprotectants in stroke
therapy. Expert Opin Pharmacother 2008;9:887-900.
17. Le Maître E, Barde SS, Palkovits M, Díaz-Heijtz R, Hökfelt TG.
Distinct features of neurotransmitter systems in the human
brain with focus on the galanin system in locus coeruleus and
dorsal raphe. Proc Natl Acad Sci U S A 2013;110:E536-45.
18. Lang R, Gundlach AL, Kofler B. The galanin peptide family:
receptor pharmacology, pleiotropic biological actions, and im-
portance in health and disease. Pharmacol Ther 2007;115:177-
207.
19. Ma X, Tong YG, Schmidt R, Brown W, Payza K, Hódzic L, Pou C,
Godbout C, Hökfelt T, Xu ZQ. Effects of galanin receptor ago-
nists on locus coeruleus neurons. Brain Res 2001;919:169-74.
20. Cheung CC, Hohmann JG, Clifton DK, Steiner RA. Distribu-
tion of galanin messenger RNA-expressing cells in murine brain
and their regulation by leptin in regions of the hypothalamus.
Neuroscience 2001;103:423-32.
21. Elliott-Hunt CR, Marsh B, Bacon A, Pope R, Vanderplank P,
Wynick D. Galanin acts as a neuroprotective factor to the hip-
 pocampus. Proc Natl Acad Sci U S A 2004;101:5105-10.
22. Ceresini G, Marchini L, Fabbo A, Freddi M, Pasolini G, Reali
N, Troglio G, Valenti G. Evaluation of circulating galanin levels
after exercise-induced pituitary hormone secretion in man. Me-
tabolism 1997;46:282-6.
23. Khoshbouei H, Cecchi M, Morilak DA. Modulatory effects of
galanin on 5-HT neurons in dorsal raphe nucleus. J Neurosci
Methods 2001;109:71-80.
24. Cully JA, Gfeller JD, Heise RA, Ross MJ, Teal CR, Kunick ME.
Geriatric depression, medical diagnosis, and functional recov-
ery during acute rehabilitation. Arch Phys Med Rehabil 2005;86:
2256-60.
25. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F.
Poststroke dementia. Lancet Neurol 2005;4:752-9.
26. Li W, Ling S, Yang Y, Hu Z, Davies H, Fang M. Systematic hy-
pothesis for post-stroke depression caused inflammation and
neurotransmission and resultant on possible treatments. Neuro
Endocrinol Lett 2014;35:104-9.
27. Barreda-Gomez G, Lombardero L, Giralt MT, Manuel I, Ro-
driguez-Puertas R. Effects of galanin subchronic treatment on
memory and muscarinic receptors. Neuroscience 2015;293:23-
34.
28. Kofler B, Liu ML, Jacoby AS, Shine J, Iismaa TP. Molecular
cloning and characterisation of the mouse preprogalanin gene.
Gene 1996;182:71-5.
29. Davidson S, Lear M, Shanley L, Hing B, Baizan-Edge A, Her-
wig A, Quinn JP, Breen G, McGuffin P, Starkey A, Barrett P,
MacKenzie A. Differential activity by polymorphic variants of
a remote enhancer that supports galanin expression in the hypo-
thalamus and amygdala: implications for obesity, depression and
alcoholism. Neuropsychopharmacology 2011;36:2211-21.
30. Blakeman KH, Hao JX, Xu XJ, Jacoby AS, Shine J, Crawley JN,
Iismaa T, Wiesenfeld-Hallin Z. Hyperalgesia and increased neu-
ropathic pain-like response in mice lacking galanin receptor 1
receptors. Neuroscience 2003;117:221-7.
31. Sevcik J, Finta EP, Illes P. Galanin receptors inhibit the sponta-
neous firing of locus coeruleus neurones and interact with mu-
opioid receptors. Eur J Pharmacol 1993;230:223-30.
32. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin recep-
tor subtypes. Trends Pharmacol Sci 2000;21:109-17.
33. Wang YJ, Yang YT, Li H, Liu PZ, Wang CY, Xu ZQ. Plasma
galanin is a biomarker for severity of major depressive disorder.
Int J Psychiatry Med 2014;48:109-19.
34. Hohmann JG, Juréus A, Teklemichael DN, Matsumoto AM,
Clifton DK, Steiner RA. Distribution and regulation of galanin
receptor 1 messenger RNA in the forebrain of wild type and
galanin-transgenic mice. Neuroscience 2003;117:105-17.
35. Larm JA, Shen PJ, Gundlach AL. Differential galanin receptor 1
and galanin expression by 5-HT neurons in dorsal raphe nucle-
us of rat and mouse: evidence for species-dependent modula-
tion of serotonin transmission. Eur J Neurosci 2003;17:481-93.
36. Elliott-Hunt CR, Pope RJ, Vanderplank P, Wynick D. Activation
of the galanin receptor 2 (GalR2) protects the hippocampus
from neuronal damage. J Neurochem 2007;100:780-9.
37. Sun YG, Gu XL, Lundeberg T, Yu LC. An antiinociceptive role of
galanin in the arcuate nucleus of hypothalamus in intact rats
and rats with inflammation. Pain 2003;106:143-50.
38. Ceresini G, Fabbo A, Freddi M, Maggio M, Reali N, Troglio G,
Valenti G. Concomitant evaluation of plasma galanin and cat-
echolamine levels during a cold pressor test in healthy human
male and female subjects. Horm Res 1997;48:268-73.
39. Yoshitake T, Reenilä I, Ogren SO, Hökfelt T, Kehr J. Galanin
attenuates basal and antidepressant drug-induced increase of
extracellular serotonin and noradrenaline levels in the rat hip-
pocampus. Neurosci Lett 2003;339:239-42.
40. Kehr J, Yoshitake T, Wang FH, Wynick D, Holmberg K, Lendahl
U, Bartfai T, Yamaguchi M, Hökfelt T, Ogren SO. Microdialysis
in freely moving mice: determination of acetylcholine, sero-
tonin and noradrenaline release in galanin transgenic mice. J
Neurosci Methods 2001;109:71-80.
41. Hökfelt T, Broberger C, Diez M, Xu ZQ, Shi T, Kopp J, Zhang
X, Holmberg K, Landry M, Koistinaho J. Galanin and NPY, two
peptides with multiple putative roles in the nervous system.
Horm Metab Res 1999;31:330-4.
42. Wynick D, Thompson SW, McMahon SB. The role of galanin
as a multi-functional neuropeptide in the nervous system. Curr
Opin Pharmacol 2001;1:73-7.
43. Holm L, Theodorsson E, Hökfelt T, Theodorsson A. Effects of
intracerebroventricular galanin or a galanin receptor 2/3 agonist
https://doi.org/10.5115/acb.2016.49.4.223
on the lesion induced by transient occlusion of the middle cerebral artery in female rats. Neuropeptides 2011;45:17-23.
44. Holm L, Hilkse S, Adori C, Theodorsson E, Hökfelt T, Theodorsson A. Changes in galanin and GalR1 gene expression in discrete brain regions after transient occlusion of the middle cerebral artery in female rats. Neuropeptides 2012;46:19-27.
45. Raghavendra Rao VL, Bowen KK, Dhodha VK, Song G, Franklin JL, Gavva NR, Dempsey RJ. Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem 2002;83:1072-86.
46. De Michele M, Sancesario G, Toni D, Ciuffoli A, Bernardi G, Sette G. Specific expression of galanin in the peri-infarct zone after permanent focal cerebral ischemia in the rat. Regul Pept 2006;134:38-45.
47. Gillen R, Tennhen H, McKee TE, Gernert-Dott P, Affleck G. Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients. Arch Phys Med Rehabil 2001;82:1645-9.
48. Pohjasvaara T, Vataja R, Leppävuori A, Erkinjuntti T. Depression after cerebrovascular disorders. Duodecim 2001;117:397-403.
49. Schöttke H, Giabbiconi CM. Post-stroke depression and post-stroke anxiety: prevalence and predictors. Int Psychogeriatr 2015;27:1805-12.
50. Ali A, Randhawa PK, Jaggi AS. Stress and opioids: role of opioids in modulating stress-related behavior and effect of stress on morphine conditioned place preference. Neurosci Biobehav Rev 2015;51:138-50.
51. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke 2013;44:1105-12.
52. Loubinoux I, Kronenberg G, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L, Popa-Wagner A. Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med 2012;16:1961-9.
53. Crowe C, Coen RF, Kidd N, Hevey D, Cooney J, Harbison J. A qualitative study of the experience of psychological distress post-stroke. J Health Psychol 2015 Apr 30 [Epub]. https://doi.org/10.1177/1359105315581067.
54. Narváez M, Borroto-Escuela DO, Millón C, Gago B, Flores-Burgess A, Santín L, Fuze K, Narváez JA, Diaz-Cabiale Z. Galanin receptor 2-neuropeptide Y Y1 receptor interactions in the dentate gyrus are related with antidepressant-like effects. Brain Struct Funct 2016;221:4129-39.
55. Lundström L, Elmoquist A, Bartfai T, Langel U. Galanin and its receptors in neurological disorders. Neuromolecular Med 2005;7:157-80.
56. Kinney JW, Sanchez-Alavez M, Barr AM, Criado JR, Crawley JN, Behrens MM, Henriksen SJ, Bartfai T. Impairment of memory consolidation by galanin correlates with in vivo inhibition of both LTP and CREB phosphorylation. Neurobiol Learn Mem 2009;92:429-38.
57. Hawes JJ, Brunzell DH, Narasimhaiah R, Langel U, Wynick D, Picciotto MR. Galanin protects against behavioral and neurochemical correlates of opiate reward. Neuropsychopharmacology 2008;33:1864-73.
58. Juhasz G, Dunham JS, McKay S, Thomas E, Downey D, Chase D, Lloyd-Williams K, Toth ZG, Platt H, Mekli K, Fayton A, Elliott R, Williams SR, Anderson IM, Deakin JE. The CREB1-DBNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactions. Biol Psychiatry 2011;69:762-71.
59. Sweerts BW, Jarrott B, Lawrence AJ. Expression of prepro-galanin mRNA following acute and chronic restraint stress in brains of normotensive and hypertensive rats. Brain Res Mol Brain Res 1999;69:113-23.
60. Kuteeva E, Hökfelt T, Wardi T, Ogren SO. Galanin, galanin receptor subtypes and depression-like behaviour. Exs 2010;102:163-81.
61. Lu X, Sharkey L, Bartfai T. The brain galanin receptors: targets for novel antidepressant drugs. CNS Neurol Disord Drug Targets 2007;6:183-92.
62. Mo Y, Yao H, Song H, Wang X, Chen W, Abulizi J, Xu A, Tang Y, Han X, Li Z. Alteration of behavioral changes and hippocampus galanin expression in chronic unpredictable mild stress-induced depression rats and effect of electroacupuncture treatment. Evid Based Complement Alternat Med 2014;2014:179796.
63. Juhasz G, Hullam G, Eszlari N, Gonda X, Antal P, Anderson IM, Hökfelt TG, Deakin JE, Bagdy G. Brain galanin system genes interact with life stresses in depression-related phenotypes. Proc Natl Acad Sci U S A 2014;111:E1666-73.
64. Quinn JP, Warburton A, Myers P, Savage AL, Bubb VJ. Polymorphic variation as a driver of differential neuropeptide gene expression. Neuropeptides 2013;47:395-400.
65. Dír Nagl U, Iadecola C, Moskowitz MA. Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999;22:391-7.
66. Lo EH. Degeneration and repair in central nervous system disease. Nat Med 2010;16:1205-9.
67. Campanella M, Sciorati C, Tarozzo G, Beltramo M. Flow cytometric analysis of inflammatory cells in ischemic rat brain. Stroke 2002;33:586-92.
68. Kriz J. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006;18:145-57.
69. Famakin BM. The immune response to acute focal cerebral ischemia and associated post-stroke immunodepression: a focused review. Aging Dis 2014;5:307-26.
70. Lee CH, Won MH. Change of peroxisome proliferator-activated receptor gamma expression pattern in the gerbil dentate gyrus after transient global cerebral ischemia. Anat Cell Biol 2014;47:111-6.
71. Kim H, Bae S, Kwon KY, Hwang YI, Kang JS, Lee WJ. A combinatorial effect of acetaminophen and oriental herbs on the regulation of inflammatory mediators in microglia cell line, BV2. Anat Cell Biol 2015;48:244-50.
72. Carvalho-Tavares J, Hickey MJ, Hutchison J, Michaud J, Sutcliffe IT, Kubes P. A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000;87:1141-8.
73. Lang R, Gundlach AL, Holmes FE, Hobson SA, Wynick D, Hökfelt T, Kofler B. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol Rev 2015;67:118-75.

74. Pintér E, Pozsgai G, Hajna Z, Helyes Z, Szolcsányi J. Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions. Br J Clin Pharmacol 2014;77:5-20.

75. Marrero JA, Matkowskij KA, Yung K, Hecht G, Benya RV. Dextran sulfate sodium-induced murine colitis activates NF-kappaB and increases galanin-1 receptor expression. Am J Physiol Gastrointest Liver Physiol 2000;278:G797-804.

76. Matkowskij K, Royan SV, Blunier A, Hecht G, Rao M, Benya RV. Age-dependent differences in galanin-dependent colonic fluid secretion after infection with Salmonella Typhimurium. Gut 2009;58:1201-6.

77. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 2007;26:5762-71.

78. Blackshear A, Yamamoto M, Anderson BJ, Holmes PV, Lundström L, Langel U, Robinson JK. Intracerebroventricular administration of galanin or galanin receptor subtype 1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus. Peptides 2007;28:1120-4.

79. Metcalf CS, Klein BD, McDougle DR, Zhang L, Smith MD, Bulag J, White HS. Analgesic properties of a peripherally acting and GaR2 receptor-preferring galanin analog in inflammatory, neuropathic, and acute pain models. J Pharmacol Exp Ther 2015;352:185-93.

80. Uehara T, Kanazawa T, Klemm J, Uchibori R, Tsukahara T, Urabe M, Kume A, Misawa K, Carey TE. Galanin and galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci 2014;105:72-80.

81. Kanazawa T, Iwashita T, Kommareddi P, Nair T, Misawa K, Misawa Y, Ueda Y, Tono T, Carey TE. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors. Oncogene 2007;26:5762-71.

82. McDonald AC, Schuijers JA, Gundlach AL, Grills BL. Galanin treatment offsets the inhibition of bone formation and down-regulates the increase in mouse calvarial expression of TNFalpha and GalR2 mRNA induced by chronic daily injections of an injurious vehicle. Bone 2007;40:895-903.

83. Linden T, Skoog I, Fagerberg B, Steen B, Blomstrand C. Cognitive impairment and dementia 20 months after stroke. Neuroepidemiology 2004;23:45-52.

84. Urisin MH, Bergland A, Fure B, Törstad A, Treit A, Ihle-Hansen H. Balance and mobility as predictors of post-stroke cognitive impairment. Dement Geriatr Cogn Dis Extra 2015;5:203-11.

85. Bour A, Rasquin S, Boreas A, Limburg M, Verhey F. How predictive is the MMSE for cognitive performance after stroke? J Neurol 2010;257:630-7.

86. Werring DJ, Gregoire SM, Cipolotti L. Cerebral microbleeds and vascular cognitive impairment. J Neurol Sci 2010;299:131-5.

87. Kliper E, Ben Assayag E, Korecz AD, Auriel E, Shopin L, Hallevi H, Shenhar-Tsarfaty S, Mike A, Artzi M, Klovatch I, Borenstein NM, Ben Bashat D. Cognitive state following mild stroke: a matter of hippocampal mean diffusivity. Hippocampus 2016;26:161-9.

88. Zhang Z, Pang P, Shi M, Zhu Y, Bo P. Elevated galanin may predict the risk of type 2 diabetes mellitus for development of Alzheimer’s disease. Mech Ageing Dev 2015;150:20-6.

89. Wrenn CC, Kinney JW, Marriott LK, Holmes A, Harris AP, Saa-vedra MC, Starosta G, Innerfield CE, Jacoby AS, Shine J, Ismaa TP, Wenk GL, Crawley JN. Learning and memory performance in mice lacking the GAL-R1 subtype of galanin receptor. Eur J Neurosci 2004;19:1384-96.

90. Elvander E, Schott PA, Sandin J, Bjelke B, Kehr J, Yoshitake T, Ogren SO. Intraocular muscularin ligands and galanin: influence on hippocampal acetylcholine and cognition. Neuroscience 2004;126:541-57.

91. Barrera C, Richaud-Thiriez B, Rocchi S, Rousset S, Grignon F, Laboissière A. New commercially available IgG kits and time-resolved fluorometric IgE assay for diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Clin Vaccine Immunol 2016;23:196-203.

92. Cheng Y, Yu LC. Galanin up-regulates the expression of M1 muscarinic acetylcholine receptor via the ERK signaling pathway in primary cultured prefrontal cortical neurons. Neurosci Lett 2015;590:161-5.

93. Ogren SO, Kehr J, Schott PA. Effects of ventral hippocampal galanin on spatial learning and on in vivo acetylcholine release in the rat. Neuroscience 1996;75:1127-40.

94. Ukaï M, Miura M, Kameyama T. Effects of galanin on passive avoidance response, elevated plus-maze learning, and spontaneous alternation performance in mice. Peptides 1995;16:1283-6.

95. Fisone G, Wu CF, Consolo S, Nordström O, Brynne N, Bartfai T, Melander T, Hökfelt T. Galanin inhibits acetylcholine release in the ventral hippocampus of the rat: histochemical, autoradiographic, in vivo, and in vitro studies. Proc Natl Acad Sci U S A 1987;84:7339-43.

96. Wang HY, Wild KD, Shank RP, Lee DH. Galanin inhibits acetylcholine release from rat cerebral cortex via a pertussis toxin-sensitive G(i) protein. Neuropeptides 1999;33:197-205.

97. O’Meara G, Coumios U, Ma SY, Kehr J, Mahoney S, Bacon A, Allen SJ, Holmes F, Kahl U, Wang FH, Kearns IR, Ove-Ogren S, Dawbarn D, Muñson EJ, Davies C, Dawson G, Wynick D. Galanin regulates the postnatal survival of a subset of basal forebrain cholinergic neurons. Proc Natl Acad Sci U S A 2000;97:11569-74.

98. Massey PV, Warburton EC, Wynick D, Brown MW, Bashir ZI. Galanin regulates spatial memory but not visual recognition memory or synaptic plasticity in perirhinal cortex. Neurophar-
99. Perez SE, Wynick D, Steiner RA, Mufson EJ. Distribution of galaninergic immunoreactivity in the brain of the mouse. J Comp Neurol 2001;434:158-85.

100. Mataró M, Poca MA, Del Mar Matarin M, Catalan R, Sahuquillo J, Galard R. CSF galanin and cognition after shunt surgery in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2003;74:1272-7.